KLRA Kailera Therapeutics, Inc. - Common stock
$18.21
Price · Aug 19, 2026
Fundamentals as of Aug 12, 2026
52W Range
$16–$28
15% of range
Analyst Rating
BUY
12 analysts
Price Target
$42
+133% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
KLRA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$18.21
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$16 – $28
KLRA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
KLRA
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
KLRA
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
KLRA
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
KLRA
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
KLRA
Peer Median
KLRA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
12 analysts
- Strong Buy 5 41.7%
- Buy 6 50.0%
- Hold 1 8.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
5 analysts · 2026-08-18
Median
$41.00
← Below all targets
$18.21
Low
$30.00
High
$57.00
Median target
$41.00
+125.2%
Mean target
$42.40
+132.8%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.14%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-1.09 | $-0.77 | -0.33% |
| March 31, 2026 | $-0.64 | $-0.69 | 0.05% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| KLRA | — | — | — | — | — | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| COAG | — | — | — | — | — | — |
| MLYS | $2.96B | -15.8 | — | — | -32.2% | — |
| VERA | — | -10.9 | — | — | -55.9% | — |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
| GENB | — | — | — | — | — | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 20
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $160M | |
| Short-term Investments | $386M | |
| Prepaid Expense | $11M | |
| Other Current Assets | $2M | |
| Current Assets | $558M | |
| PP&E (Net) | $2M | |
| Other Non-current Assets | $3M | |
| Total Assets | $692M | |
| Accounts Payable | $8M | |
| Accrued Liabilities | $38M | |
| Current Liabilities | $46M | |
| Capital Leases | $10M | |
| Other Non-current Liabilities | $270.0K | |
| Total Liabilities | $56M | |
| Common Stock | $0 | |
| Retained Earnings | $-369M | |
| AOCI | $229.0K | |
| Stockholders' Equity | $-356M | |
| Liabilities + Equity | $692M | |
| Shares Outstanding | 19,048 |
Income Statement 11
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| R&D Expense | $101M | $71M | |
| SG&A Expense | $20M | $14M | |
| Operating Expenses | $121M | $85M | |
| Operating Income | $-121M | $-85M | |
| Other Non-op | $72.0K | $6M | |
| Net Income | $-111M | $-79M | |
| EPS (Basic) | $-1.09 | $-3650.00 | |
| EPS (Diluted) | $-1.09 | $-3650.00 | |
| Shares (Basic) | 102,226,608 | 21,607 | |
| Shares (Diluted) | 102,226,608 | 21,607 | |
| EBITDA | $-121M | $-85M |
Balance Sheet 20
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Cash & Equivalents | $130M | $112M | |
| Short-term Investments | $786M | $407M | |
| Prepaid Expense | $12M | $11M | |
| Other Current Assets | $395.0K | $360.0K | |
| Current Assets | $929M | $530M | |
| PP&E (Net) | $2M | $2M | |
| Other Non-current Assets | $90.0K | $6M | |
| Total Assets | $1.21B | $625M | |
| Accounts Payable | $19M | $7M | |
| Accrued Liabilities | $63M | $47M | |
| Current Liabilities | $84M | $55M | |
| Capital Leases | $9M | $9M | |
| Other Non-current Liabilities | $135.0K | $201.0K | |
| Total Liabilities | $93M | $64M | |
| Common Stock | $0 | $0 | |
| Retained Earnings | $-559M | $-448M | |
| AOCI | $-2M | $-532.0K | |
| Stockholders' Equity | $1.12B | $-432M | |
| Liabilities + Equity | $1.21B | $625M | |
| Shares Outstanding | 129,620,370 | 29,953 |
Cash Flow 6
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| D&A | $101.0K | $101.0K | |
| Stock-based Comp | $8M | $4M | |
| Other Non-cash | · | $7M | |
| Operating Cash Flow | $-78M | $-68M | |
| Investing Cash Flow | $-571M | $23M | |
| Financing Cash Flow | $667M | $-3M |
Profitability 2
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| ROA | -18.4% | -25.2% | |
| ROE | -19.9% | 36.5% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Current Ratio | 11.1 | 9.7 | |
| Quick Ratio | 11.0 | 9.5 |
Valuation (TTM) 3
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Market Cap | $2.86B | · | |
| P/B | 2.6 | · | |
| P / Tangible Book | 2.6 | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 15 insiders · 8 officers · 7 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Ronald C Renaud JR | CEO & President | June 9, 2026 M | 38,094 | 0 | 0 | $0 |
| Douglas W. Pagan | Chief Financial Officer | April 16, 2026 A | — | 0 | 0 | $0 |
| Paul D. Burgess | Chief Operating Officer & Chief Business Officer | April 16, 2026 A | — | 0 | 0 | $0 |
| Kathleen Tregoning | Chief Corporate Affairs Officer | July 6, 2026 A | — | 0 | 0 | $0 |
| Scott M. Wasserman | Chief Medical Officer | April 16, 2026 A | — | 0 | 0 | $0 |
| Jamie Beth Coleman | Chief Commercial Officer | April 16, 2026 A | — | 0 | 0 | $0 |
| Scott Akamine | Chief Legal Officer | April 16, 2026 A | — | 0 | 0 | $0 |
| Paula Cloghessy | Chief People Officer | April 16, 2026 A | — | 0 | 0 | $0 |
| Christopher Hite | Director | April 16, 2026 A | — | 0 | 0 | $0 |
| Frank Clyburn | Director | April 16, 2026 A | — | 0 | 0 | $0 |
| Andrew T. Kaplan | Director | April 16, 2026 A | 26,255,581 | 1 | 0 | $134,375,008 |
| Adam Koppel | Director | April 16, 2026 A | 22,583,268 | 1 | 0 | $25,000,000 |
| Martin Mackay | Director | April 16, 2026 A | — | 0 | 0 | $0 |
| John F Milligan | Director | April 16, 2026 A | — | 0 | 0 | $0 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | April 20, 2026 C | 2,034,133 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| BCLS Fund IV Investments, L.P. | April 23, 2026 | 17.43% | Initial filing | Passive investment | SEC |
| BCPE Perseus Investor, LP | April 23, 2026 | 20.27% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 15 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 34,051 SH | Aug. 8, 2026 | Daily |
| IWO · iShares Trust | 0.04% | 284,289 SH | Aug. 8, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.03% | 265,577 SH | Aug. 8, 2026 | Daily |
| IWM · iShares Trust | 0.03% | 1,153,762 SH | Aug. 8, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.02% | 3,651 SH | Aug. 8, 2026 | Daily |
| VBK · VANGUARD INDEX FUNDS | 0.02% | 487,994 SH | Aug. 8, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 12,500 SH | Aug. 8, 2026 | Daily |
| IWN · iShares Trust | 0.02% | 135,242 SH | Aug. 8, 2026 | Daily |
| ISCB · iShares Trust | 0.01% | 1,996 SH | Aug. 8, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 476,091 SH | Aug. 8, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.01% | 848,546 SH | Aug. 8, 2026 | Daily |
| ITOT · iShares Trust | 0.00% | 62,165 SH | Aug. 8, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 12,236 SH | Aug. 8, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,180,411 SH | Aug. 8, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,839 SH | Aug. 8, 2026 | Daily |